1,1'-p-xylylbis<4,8,11-tris(tert-butyloxycarbonyl)-1,4,8,11-tetraazacyclotetradecane> | 175854-48-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1'-p-xylylbis<4,8,11-tris(tert-butyloxycarbonyl)-1,4,8,11-tetraazacyclotetradecane>
• 英文别名: 1,1'-p-xylylbis(4,8,11-tris(tert-butyloxycarbonyl)-1,4,8,11-tetraazacyclotetradecane)；Tritert-butyl 11-[[4-[[4,8,11-tris(tert-butoxycarbonyl)-1,4,8,11-tetrazacyclotetradec-1-yl]methyl]phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane-1,4,8-tricarboxylate；tritert-butyl 11-[[4-[[4,8,11-tris[(2-methylpropan-2-yl)oxycarbonyl]-1,4,8,11-tetrazacyclotetradec-1-yl]methyl]phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane-1,4,8-tricarboxylate
• CAS: 175854-48-5
• 化学式: C₅₈H₁₀₂N₈O₁₂
• 分子量: 1103.49
• InChiKey: QFUXFQRXAFYLHV-UHFFFAOYSA-N

物化性质

• 沸点：
  954.0±65.0 °C(Predicted)
• 密度：
  1.086±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  78
• 可旋转键数：
  16
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  184
• 氢给体数：
  0
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  1,1'-p-xylylbis<4,8,11-tris(tert-butyloxycarbonyl)-1,4,8,11-tetraazacyclotetradecane> 在 盐酸 作用下， 反应 1.0h， 以90%的产率得到普乐沙福
  参考文献：
  名称：

  Brandes, Stephane, Bulletin de la Societe Chimique de France, 1996, vol. 133, # 1, p. 65 - 73

  摘要：

  DOI：
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 sodium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 50.0h， 生成 1,1'-p-xylylbis<4,8,11-tris(tert-butyloxycarbonyl)-1,4,8,11-tetraazacyclotetradecane>
  参考文献：
  名称：

  Brandes, Stephane, Bulletin de la Societe Chimique de France, 1996, vol. 133, # 1, p. 65 - 73

  摘要：

  DOI：

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF XYLENE LINKED CYCLAM COMPOUNDS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE COMPOSÉS DE CYCLAME LIÉS AU XYLÈNE
  申请人：FRESENIUS KABI ONCOLOGY LTD

  公开号：WO2017037639A1

  公开（公告）日：2017-03-09

  The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of expensive chemicals, hazardous reagents or tedious purification techniques. Invention also provides novel intermediate useful for preparation of desired compound in high purity.

  本发明涉及一种改进的制备二甲苯链环戊氨基甲酸化合物的方法。更具体地说，该发明提供了一种制备高纯度普利西法的方法，不涉及使用昂贵的化学品、危险试剂或繁琐的纯化技术。该发明还提供了用于制备所需高纯度化合物的新型中间体。
• Process for the preparation of xylene linked cyclam compounds
  申请人：FRESENIUS KABI ONCOLOGY LTD.

  公开号：US10544109B2

  公开（公告）日：2020-01-28

  The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of expensive chemicals, hazardous reagents or tedious purification techniques. Invention also provides novel intermediate useful for preparation of desired compound in high purity.

  本发明涉及一种改良的二甲苯链环化合物制备工艺。更具体地说，本发明提供了一种制备高纯度 plerixafor 的工艺，该工艺无需使用昂贵的化学品、危险试剂或繁琐的纯化技术。本发明还提供了用于制备高纯度所需化合物的新型中间体。
• New Bicyclam−AZT Conjugates:  Design, Synthesis, Anti-HIV Evaluation, and Their Interaction with CXCR-4 Coreceptor
  作者：Jean Dessolin、Pascale Galea、Patrick Vlieghe、Jean-Claude Chermann、Jean-Louis Kraus

  DOI：10.1021/jm980358u

  日期：1999.1.1

  We report the synthesis of mono- and bis-tetraazamacrocycle-AZT conjugates. All new compounds were screened for their ability to inhibit HIV-1 replication in MT4 cell line and were compared to AZT alone. It appears that N-protected covalent prodrugs are equipotent to AZT as inhibitor of HIV replication, while N-deprotected analogues exhibit both higher activity and selectivity against HIV-infected cells. The most active antiviral compounds 27, 28, 34, and 35 were then tested for their binding capability to CXCR-4 receptor. N-Boc analogues 27 and 34 were only weakly effective; in contrast, N-deprotected conjugates 28 and 35 were antagonists to 12G5 mAb binding until 0.05 and 5 mu g/mL, respectively. The stability of compound 28 in human plasma was evaluated, and half-life was found to be approximately 8 h in the described conditions. All these results seem to demonstrate the confidence of our prodrug approach, with analogue 28 emerging as the best candidate as lead compound in HIV-1 polytherapy perspective.
• A PROCESS FOR THE PREPARATION OF XYLENE LINKED CYCLAM COMPOUNDS
  申请人：Fresenius Kabi Oncology Ltd

  公开号：EP3344608B1

  公开（公告）日：2019-10-23
• Brandes, Stephane, Bulletin de la Societe Chimique de France, 1996, vol. 133, # 1, p. 65 - 73
  作者：Brandes, Stephane

  DOI：——

  日期：——